Navidea Biopharmaceuticals (NAVB) has risen sharply, recording gains of 2.24% in the past 4 weeks. However, the stock has corrected -11% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 1.19% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
The stock has recorded a 20-day Moving Average of 4.71% and the 50-Day Moving Average is 12.78%. Navidea Biopharmaceuticals (NYSEMKT:NAVB): On Fridays trading session , Opening price of the stock was $0.5199 with an intraday high of $0.5549. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $0.515. However, the stock managed to close at $0.516, a loss of 0.77% for the day. On the previous day, the stock had closed at $0.52. The total traded volume of the day was 787,985 shares.
The company Insiders own 1.2% of Navidea Biopharmaceuticals shares according to the proxy statements. Institutional Investors own 32.27% of Navidea Biopharmaceuticals shares.
Navidea Biopharmaceuticals, Inc. is a precision medicine company focused on the development and commercialization of precision diagnostics, therapeutics and radiopharmaceutical agents. The Company is developing multiple precision-targeted products based on the Manocept platform. The Manocept platform serves as the molecular backbone of Lymphoseek (technetium Tc 99m tilmanocept) injection, the first product developed by the Company based on the platform. Lymphoseek is a receptor-targeted, small-molecule radiopharmaceutical used in the evaluation of lymphatic basins that may have cancer involvement in patients. NAV4694 is a fluorine-18 radiolabeled PET imaging agent being developed as an aid in the diagnosis of patients with signs or symptoms of Alzheimers disease (AD) and mild cognitive impairment. NAV5001 is an iodine-123 radiolabeled SPECT imaging agent being developed as an aid in the diagnosis of Parkinsons disease (PD) and other movement disorders.